|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1684-1689.
Prepublished online as a Blood First Edition Paper on May 11, 2006; DOI 10.1182/blood-2005-11-011486.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies
Karen Stephens,
Molly Weaver,
Kathleen A. Leppig,
Kyoko Maruyama,
Peter D. Emanuel,
Michelle M. Le Beau, and
Kevin M. Shannon
From the Departments of Medicine, Laboratory Medicine, Pathology, and Pediatrics, University of Washington, Seattle; the Division of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, University of Alabama at Birmingham; the Department of Medicine, Section of Hematology/Oncology, University of Chicago, IL; and the Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco.
To identify the mechanism of loss of heterozygosity (LOH) and potential modifier gene(s), we investigated the molecular basis of somatic NF1 inactivation in myeloid malignancies from 10 children with neurofibromatosis type 1. Loci across a minimal 50-Mb region of primarily the long arm of chromosome 17 showed LOH in 8 cases, whereas a less than 9-Mb region of loci flanking NF1 had LOH in the remaining 2 cases. Two complementary techniques, quantitative polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH), were used to determine whether the copy number at loci that showed LOH was 1 or 2 (ie, deleted or isodisomic). The 2 cases with LOH limited to less than 9 Mb were intrachromosomal deletions. Among the 8 leukemias with 50-Mb LOH segments, 4 had partial uniparental isodisomy and 4 had interstitial uniparental isodisomy. These isodisomic cases showed clustering of the centromeric and telomeric LOH breakpoints. This suggests that the cases with interstitial uniparental isodisomy arose in a leukemia-initiating cell by double-homologous recombination events at intervals of preferred mitotic recombination. Homozygous inactivation of NF1 favored outgrowth of the leukemia-initiating cell. Our studies demonstrate that LOH analyses of loci distributed along the chromosomal length along with copy-number analysis can reveal novel mechanisms of LOH that may potentially identify regions harboring "cryptic" tumor suppressor or modifier genes whose inactivation contributes to tumorigenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood,
July 30, 2009;
114(5):
937 - 951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lange
A FISH 'n chips appetizer
Blood,
January 15, 2008;
111(2):
480 - 481.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Flotho, C. P. Kratz, and C. M. Niemeyer
How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia
Haematologica,
November 1, 2007;
92(11):
1441 - 1446.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mohamedali, J. Gaken, N. A. Twine, W. Ingram, N. Westwood, N. C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, et al.
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Blood,
November 1, 2007;
110(9):
3365 - 3373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suela, C. Largo, B. Ferreira, S. Alvarez, M. Robledo, A. Gonzalez-Neira, M. J. Calasanz, and J. C. Cigudosa
Neurofibromatosis 1, and Not TP53, Seems to Be the Main Target of Chromosome 17 Deletions in De Novo Acute Myeloid Leukemia
J. Clin. Oncol.,
March 20, 2007;
25(9):
1151 - 1152.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. Rucker, L. Bullinger, K. Dohner, and H. Dohner
In Reply
J. Clin. Oncol.,
March 20, 2007;
25(9):
1152 - 1153.
[Full Text]
[PDF]
|
 |
|
|
|